Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States

Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States &nbsp The developer is a United Kingdom-based drug development and manufacturing company, providing integrated R&D and manufacturing capabilities to accelerate entry of PIP-101 in the U.S. market. Shorla Oncology to receive the exclusive rights to commerci..